Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases

Onkologie

Volumn 35, Issue 9, 2012, Pages 487-492

  Hilgendorf, Inken ^a   Wolff, Daniel ^b   Nogai, Axel ^c   Kundt, Gnther ^a   Hahn, Joachim ^b   Holler, Ernst ^b   Uharek, Lutz ^c   Junghanss, Christian ^a   Leithuser, Malte ^a   Thiel, Eckhard ^c   Freund, Mathias ^a   Kahl, Christoph ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Advanced; Allogeneic stem cell transplantation; Chronic; Graft versus host disease; Hematological malignancies; Myeloablative conditioning; Reduced intensity conditioning

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHRONIC DISEASE; COMORBIDITY; FEMALE; GERMANY; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866840042     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000341835     Document Type: Article

References (20)

1. Baron F, Storb R, Little MT: Hematopoietic cell transplantation: Five decades of progress. Arch Med Res 2003;34:528-544.
2. Bensinger WI, Martin PJ, Storer B et al.: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-181.
3. Bensinger WI, Storb R: Allogeneic peripheral blood stem cell transplantation. Rev Clin Exp Hematol 2001;5:67-86.
4. Goldman JM, Gale RP, Horowitz MM et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108:806-814.
5. Hosing C, Saliba RM, Shahjahan M et al.: Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005;36: 157-162.
6. Loren AW, Bunin GR, Boudreau C et al.: Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:758-769.
7. Anasetti C: What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? Best Pract Res Clin Haematol 2008;21:691-697.
8. Urbano-Ispizua A, Schmitz N, de Witte T et al.: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002;29:639-646.
9. Przepiorka D, Weisdorf D, Martin P et al.: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
10. Shulman HM, Sullivan KM, Weiden PL et al.: Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
11. Alyea EP, Kim HT, Ho V et al.: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006;12: 1047-1055.
12. Schmid C, Schleuning M, Schwerdtfeger R et al.: Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108:1092-1099.
13. Oyekunle AA, Kroger N, Zabelina T et al.: Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant 2006;37:45-50.
14. Robinson SP, Goldstone AH, Mackinnon S et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-4316.
15. Kennedy GA, Butler J, Morton J et al.: Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: Very long-term follow up of a single center experience. Clin Lab Haematol 2006;28:189-197.
16. Klingebiel T, Cornish J, Labopin M et al.: Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: Impact of center size: An analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010;115:3427-3446.
17. Bader P, Kreyenberg H, Henze GHR et al.: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group. J Clin Oncol 2009;27:377-384.
18. Shaw BE, Mufti GJ, Mackinnon S et al.: Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008;42:783-789.
19. Lee SJ, Klein JP, Barrett AJ et al.: Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 2002;100:406-414.
20. Kahl C, Storer BE, Sandmaier BM et al.: Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110: 2744-2748.